drugset / Trial / NCT00323310

Safety and Efficacy of MultiHance in Pediatric Patients

NCT00323310

Phase 3 Terminated 92 enrolled Bracco Diagnostics, Inc
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study was to assess the safety and enhancing properties of the magnetic resonance imaging (MRI) contrast agent MultiHance in children aged 2 to 17 years having central nervous system (CNS) disorders.

Timeline

Start
2006-04
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gadobenate dimeglumine Diagnostic / imaging agent 0.1 mmol Intravenous